Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications.

Slassi A, Isaac M, Edwards L, Minidis A, Wensbo D, Mattsson J, Nilsson K, Raboisson P, McLeod D, Stormann TM, Hammerland LG, Johnson E.

Curr Top Med Chem. 2005;5(9):897-911. Review.

PMID:
16178734
2.
3.

New therapeutic frontiers for metabotropic glutamate receptors.

Niswender CM, Jones CK, Conn PJ.

Curr Top Med Chem. 2005;5(9):847-57. Review.

PMID:
16178730
4.

Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.

Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F.

J Cereb Blood Flow Metab. 2001 Sep;21(9):1013-33. Review.

PMID:
11524608
5.

mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy.

Löscher W, Dekundy A, Nagel J, Danysz W, Parsons CG, Potschka H.

Neuropharmacology. 2006 Jun;50(8):1006-15.

PMID:
16563443
6.

Glutamate metabotropic receptors as targets for drug therapy in epilepsy.

Moldrich RX, Chapman AG, De Sarro G, Meldrum BS.

Eur J Pharmacol. 2003 Aug 22;476(1-2):3-16. Review.

PMID:
12969743
7.
8.

Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Kew JN, Kemp JA.

Psychopharmacology (Berl). 2005 Apr;179(1):4-29. Review. Erratum in: Psychopharmacology (Berl). 2005 Oct;182(2):320.

PMID:
15731895
9.
10.

Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.

Palucha A, Pilc A.

Pharmacol Ther. 2007 Jul;115(1):116-47. Review.

PMID:
17582504
11.

Physiological roles and therapeutic potential of metabotropic glutamate receptors.

Conn PJ.

Ann N Y Acad Sci. 2003 Nov;1003:12-21. Review.

PMID:
14684432
12.

Involvement of endocannabinoid signaling in the neuroprotective effects of subtype 1 metabotropic glutamate receptor antagonists in models of cerebral ischemia.

Landucci E, Boscia F, Gerace E, Scartabelli T, Cozzi A, Moroni F, Mannaioni G, Pellegrini-Giampietro DE.

Int Rev Neurobiol. 2009;85:337-50. doi: 10.1016/S0074-7742(09)85023-X. Review.

PMID:
19607979
13.

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. Review.

PMID:
17430147
14.

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Palucha A.

Expert Opin Investig Drugs. 2006 Dec;15(12):1545-53. Review.

PMID:
17107280
15.
16.

Glutamate receptor ligands as anxiolytics.

Chojnacka-Wójcik E, Kłodzinska A, Pilc A.

Curr Opin Investig Drugs. 2001 Aug;2(8):1112-9. Review.

PMID:
11892923
18.

The promiscuous mGlu5 receptor--a range of partners for therapeutic possibilities?

Bird MK, Lawrence AJ.

Trends Pharmacol Sci. 2009 Dec;30(12):617-23. doi: 10.1016/j.tips.2009.09.008. Review.

PMID:
19892412
19.

Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.

Chua PC, Nagasawa JY, Bleicher LS, Munoz B, Schweiger EJ, Tehrani L, Anderson JJ, Cramer M, Chung J, Green MD, King CD, Reyes-Manalo G, Cosford ND.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4589-93.

PMID:
16115767
20.

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.

Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, Rao S, Washburn M, Varney MA.

J Med Chem. 2003 Jan 16;46(2):204-6.

PMID:
12519057

Supplemental Content

Support Center